Figure 2.

Molecular findings at resistance to the irreversible FGFR inhibitor futibatinib. A, Patients suffering from intrahepatic cholangiocarcinoma. B, Molecular evolution of patient MR553, suffering from an intrahepatic cholangiocarcinoma harboring a FGFR2::ERC1 fusion. C, Clinicoradiologic and molecular evolution of patient MR332, suffering from an intrahepatic cholangiocarcinoma driven by a FGFR2::BICC1 fusion. D, Patients suffering from other tumor types. The ctDNA findings are reported as VAF (%). BOR, best objective response; HGSOC, high-grade serous ovarian cancer; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; SD, stable disease.